Corvus Pharmaceuticals, Inc. Share Price
Equities
CRVS
US2210151005
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 USD | -2.03% | +3.57% | -17.61% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 71.11M 5.93B |
---|---|---|---|---|---|
Net income 2024 * | -33M -2.75B | Net income 2025 * | -45M -3.75B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.54
x | P/E ratio 2025 * |
-2.3
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.43% |
Latest transcript on Corvus Pharmaceuticals, Inc.
1 day | -2.03% | ||
1 week | +3.57% | ||
Current month | -18.54% | ||
1 month | -18.54% | ||
3 months | -29.27% | ||
6 months | +29.46% | ||
Current year | -17.61% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Miller
CEO | Chief Executive Officer | 73 | 27/14/27 |
Leiv Lea
DFI | Director of Finance/CFO | 70 | 27/14/27 |
James Rosenbaum
CTO | Chief Tech/Sci/R&D Officer | - | 21/22/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Miller
CEO | Chief Executive Officer | 73 | 27/14/27 |
Ian Clark
BRD | Director/Board Member | 62 | 03/17/03 |
Terry Gould
BRD | Director/Board Member | 67 | 01/14/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.45 | -2.03% | 124,494 |
25/24/25 | 1.48 | -1.99% | 66,282 |
24/24/24 | 1.51 | -1.31% | 90,571 |
23/24/23 | 1.53 | +6.25% | 137,350 |
22/24/22 | 1.44 | +2.86% | 130,642 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.61% | 71.11M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CRVS Stock